Nevro Corp Stock News
$9.79
-0.720 (-6.85%)
At Close: May 10, 2024
Analysts Estimate Nevro (NVRO) to Report a Decline in Earnings: What to Look Out for
07:03pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Expert Ratings For Nevro
04:02pm, Wednesday, 06'th Apr 2022 Benzinga
Within the last quarter, Nevro (NYSE:NVRO) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
2
4
1
0
Last 30D
0
0
0
1
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
02:16pm, Wednesday, 06'th Apr 2022 Benzinga
Upgrades
According to Morgan Stanley, the prior rating for Royalty Pharma PLC (NASDAQ:RPRX) was changed from Equal-Weight to Overweight. In the fourth quarter, Royalty Pharma showed an EPS of $0.80, c
Here's Why You Should Retain Nevro (NVRO) Stock For Now
03:12pm, Wednesday, 30'th Mar 2022 Zacks Investment Research
Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.
Here's Why You Should Retain Nevro (NVRO) Stock For Now
12:47pm, Wednesday, 30'th Mar 2022
Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.
Nevro stock rises after CEO buys shares worth $200K
05:57pm, Wednesday, 09'th Mar 2022 Seeking Alpha
Nevro <> stock edged higher after the medical device maker disclosed that CEO and chairman Keith Grossman bought 3.2K shares at $63.59 worth ~$200K.Grossman now holds ~169.3K…
Nevro's (NVRO) PDN Therapy Gets Noridian's Medicare Coverage
04:09pm, Wednesday, 09'th Mar 2022 Zacks Investment Research
Latest favorable coverage decision for Nevro's (NVRO) PDN Therapy by Noridian is expected to allow the former to serve a wider patient pool.
Nevro's (NVRO) PDN Therapy Gets Noridian's Medicare Coverage
12:47pm, Wednesday, 09'th Mar 2022
Latest favorable coverage decision for Nevro's (NVRO) PDN Therapy by Noridian is expected to allow the former to serve a wider patient pool.
Nevro's (NVRO) Q4 Earnings in Line, Revenues Beat Estimates
06:02pm, Thursday, 24'th Feb 2022 Zacks Investment Research
Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q4 due to soft geographical performances.
Nevro's (NVRO) Q4 Earnings in Line, Revenues Beat Estimates
02:39pm, Thursday, 24'th Feb 2022
Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q4 due to soft geographical performances.
Nevro Corp. 2021 Q4 - Results - Earnings Call Presentation
12:45am, Thursday, 24'th Feb 2022 Seeking Alpha
Nevro Corp.''s (NVRO) CEO Keith Grossman On Q4 2021 Results - Earnings Call Transcript
12:42am, Thursday, 24'th Feb 2022 Seeking Alpha
Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates
11:15pm, Wednesday, 23'rd Feb 2022 Zacks Investment Research
Nevro (NVRO) delivered earnings and revenue surprises of 0% and 0.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Nevro GAAP EPS of -$0.86 in-line, revenue of $102.76M beats by $2.06M
09:23pm, Wednesday, 23'rd Feb 2022 Seeking Alpha
Nevro press release (NVRO): Q4 GAAP EPS of -$0.86 in-line.Revenue of $102.76M (-6.3% Y/Y) beats by $2.06M.Q1 2022 Guidance: Revenue expected to be in the range of $85 Million to…
Nevro Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides First Quarter and Full-Year 2022 Guidance
09:05pm, Wednesday, 23'rd Feb 2022 PR Newswire
REDWOOD CITY, Calif., Feb. 23, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results for the fourth quarter and full-year ended December 31, 2021 and provided guidance for…
